Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Current Liabilities (2021 - 2026)

Axsome Therapeutics' Total Current Liabilities history spans 6 years, with the latest figure at $439.2 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 80.07% to $439.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $439.2 million, a 80.07% increase, with the full-year FY2025 number at $378.8 million, up 64.64% from a year prior.
  • Total Current Liabilities hit $439.2 million in Q1 2026 for Axsome Therapeutics, up from $378.8 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for AXSM hit a ceiling of $439.2 million in Q1 2026 and a floor of $24.5 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $189.1 million across 5 years, with a median of $144.0 million in 2024.
  • Biggest five-year swings in Total Current Liabilities: surged 318.64% in 2022 and later skyrocketed 43.11% in 2024.
  • Tracing AXSM's Total Current Liabilities over 5 years: stood at $96.6 million in 2022, then surged by 43.8% to $138.9 million in 2023, then surged by 65.72% to $230.1 million in 2024, then soared by 64.64% to $378.8 million in 2025, then increased by 15.94% to $439.2 million in 2026.
  • Business Quant data shows Total Current Liabilities for AXSM at $439.2 million in Q1 2026, $378.8 million in Q4 2025, and $360.3 million in Q3 2025.